Cycurion, Inc. (NASDAQ: CYCU) Announces Corrected Dividend Distribution Ratio of 0.0080 in Connection with its Previously Announced $500,000 Common Share Dividend
MCLEAN, Va., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU)…
Ring V: Night of the Samurai Press Conference Brings Together Boxing Stars from Japan and Mexico in Riyadh, Ahead of a Fiery Showdown This Saturday
Friday 26 December, 2025 The Saudi capital witnessed the official press conference…
AlphaTON Capital Corp Issues Clarification on Anduril Industries Investment Program
DOVER, DE, Dec. 17, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (NASDAQ:…
Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR…
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES…
Award-winning Short Film 'RU BA RU' Brings Powerful Storytelling to the Fore at Exclusive Delhi Screening
RU BA RU, an award-winning 29-minute short film exploring sisterhood, caste and…
Exosens and Theon extend long-term commercial agreement through 2030 to secure image intensifier tube capacity in a market constrained by growing demand
EXOSENS AND THEON EXTEND LONG-TERM COMMERCIAL AGREEMENT THROUGH 2030 TO SECURE IMAGE…
IOC Executive Board meeting 9 10 December 2025 Information for the media
26 November 2025 - The International Olympic Committee (IOC) Executive Board (EB) will hold…
The Volpi Rosse Menarini: The ‘Fantastic Ten’ are ready for the 2025 – 2026 Season
Italian wheelchair basketball team, sponsored by Menarini, was presented to the press…
Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the…